Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | TTR | P02766 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | KMO | O15229 | 2/20 | 0.42 |
| ▸ | ALDH1A3 | P47895 | 3/20 | 0.41 |
| ▸ | SLC1A5 | Q15758 | 2/20 | 0.40 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.40 |
| ▸ | S100A9 | P06702 | 1/20 | 0.39 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.39 |
| ▸ | PGR | P06401 | 1/20 | 0.39 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.39 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | ALDH3A1 | P30838 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | APP | P05067 | 1/20 | 0.38 |
| ▸ | FDPS | P14324 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL851413 | 1.00 | ALDH1A1 (0.52) | ALDH1A1TTRTSHRKMOALDH1A3 | |
| Formaldehyde SCHEMBL28088170 | 0.97 | ALDH1A1 (0.48) | ALDH1A1TTRTSHRKMOALDH1A3 | |
| SCHEMBL670107 | 0.86 | ALDH1A1 (0.52) | ALDH1A1TTRTSHRALDH1A3AOX1 | |
| SCHEMBL24512644 | 0.85 | SCN9A (0.46) | ALDH1A1TTRTSHRKMOLMNA | |
| SCHEMBL31556427 | 0.85 | SCN9A (0.46) | ALDH1A1TTRTSHRKMOLMNA | |
| SCHEMBL24512665 | 0.84 | SCN3A (0.48) | ALDH1A1TTRKMOLMNA | |
| SCHEMBL15331329 | 0.82 | ALDH1A1 (0.44) | ALDH1A1TTRTSHRKMOALDH1A3 | |
| SCHEMBL16955102 | 0.82 | KMO (0.42) | KMOSLC1A5S100A9APP | |
| SCHEMBL16950851 | 0.82 | KMO (0.42) | ALDH1A1KMOSLC1A5S100A9APP | |
| SCHEMBL24512677 | 0.82 | SCN9A (0.43) | ALDH1A1TTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4584265-A1 | NOVEL COMPOUNDS, COMPOSITIONS AND THERAPEUTIC USES THEREOF | Cambridge Enterprise Limited (GB) | 2025-07-16 | — | — | EP | disclosed |
| EP-4584266-A1 | NOVEL COMPOUNDS, COMPOSITIONS AND THERAPEUTIC USES THEREOF | Cambridge Enterprise Limited (GB) | 2025-07-16 | — | — | EP | disclosed |
| EP-4584267-A1 | NOVEL COMPOUNDS AS CK2 INHIBITORS | Cambridge Enterprise Limited (GB) | 2025-07-16 | — | — | EP | disclosed |
| EP-4584249-A1 | NOVEL COMPOUNDS AS CK2 INHIBITORS | Cambridge Enterprise Limited (GB) | 2025-07-16 | — | — | EP | disclosed |
| US-20240287060-A1 | BENZO[C][2,6]NAPHTHYRIDINE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USES THEREOF | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2024-08-29 | — | — | US | disclosed |
| WO-2024052701-A1 | NOVEL COMPOUNDS, COMPOSITIONS AND THERAPEUTIC USES THEREOF | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024052692-A1 | NOVEL COMPOUNDS AS CK2 INHIBITORS | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024052690-A1 | NOVEL COMPOUNDS, COMPOSITIONS AND THERAPEUTIC USES THEREOF | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024052702-A1 | NOVEL COMPOUNDS AS CK2 INHIBITORS | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2024-03-14 | — | — | WO | disclosed |
| EP-4301752-A1 | BENZO[C][2,6]NAPHTHYRIDINE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USES THEREOF | Cambridge Enterprise Limited (GB) | 2024-01-10 | — | — | EP | disclosed |
| US-11866436-B2 | Benzo[c][2,6]naphthyridine derivatives, compositions and therapeutic uses thereof | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2024-01-09 | — | — | US | disclosed |
| CN-117295736-A | Benzo [ C ] [2,6] naphthyridine derivatives, compositions thereof and therapeutic uses thereof | 剑桥实业有限公司 | 2023-12-26 | — | — | CN | disclosed |
| CN-116615199-A | Heterocyclic compounds as diacylglycerol kinase inhibitors and uses thereof | 株式会社LG化学 | 2023-08-18 | — | — | CN | disclosed |
| US-20230250097-A1 | BENZO[C][2,6]NAPHTHYRIDINE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USES THEREOF | Apollo Therapeutics Limited (GB) | 2023-08-10 | — | — | US | disclosed |
| WO-2022185041-A1 | BENZO[C][2,6]NAPHTHYRIDINE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USES THEREOF | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2022-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250097-A1 | BENZO[C][2,6]NAPHTHYRIDINE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USES THEREOF | CSNK1A1, CSNK1D, CSNK2A1 | ALDH1A1 2913/4885TTR 1318/4885TSHR 2934/4885 |
| US-11866436-B2 | Benzo[c][2,6]naphthyridine derivatives, compositions and therapeutic uses thereof | ABCB11, CEL, NDC1 | ALDH1A1 681/4885TTR 679/4885TSHR 4461/4885 |
| US-20240287060-A1 | BENZO[C][2,6]NAPHTHYRIDINE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USES THEREOF | CSNK1A1, CSNK1D, CSNK2A1 | ALDH1A1 2913/4885TTR 1318/4885TSHR 2934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.